Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Philippines Reports Drug Makers Volunteered Price Cuts On 23 Drugs

This article was originally published in PharmAsia News

Executive Summary

The Philippines authorities report that although drug makers fell short of the 21 "essential" medicines whose prices they were asked to cut by 50 percent, they did propose reductions in the prices of 23 other drugs. The National Drug Policy unit of the Health Department is reviewing the 23 additional drugs listed by pharmaceutical companies as those with prices they would cut by 10 percent to 50 percent. The proposals still have to be approved along with a government response to ordered cuts in the prices of the six essential drugs the companies did not volunteer to cut. (Click here for more

The Philippines authorities report that although drug makers fell short of the 21 "essential" medicines whose prices they were asked to cut by 50 percent, they did propose reductions in the prices of 23 other drugs. The National Drug Policy unit of the Health Department is reviewing the 23 additional drugs listed by pharmaceutical companies as those with prices they would cut by 10 percent to 50 percent. The proposals still have to be approved along with a government response to ordered cuts in the prices of the six essential drugs the companies did not volunteer to cut. (Click here for more)

"Pharmaceutical Firms Offer To Cut More Drug Prices" - BusinessWorld (Philippines) (7/22/09)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072266

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel